bioecon Member area
Technology · Services, governance & capital / Regulatory & legal

HTA dossier preparation

Health-economic evidence packages — systematic clinical-evidence reviews, cost-effectiveness and budget-impact modeling, patient-perspective data — that a biopharma manufacturer must assemble to win pricing and reimbursement approval from a national HTA body (NICE, G-BA, CADTH), prepared by specialty consultancies against strict statutory deadlines (56 days for a NICE Single Technology Appraisal), increasingly using AI to compress a traditionally months-long process.

Tech Policy & Assessment Maturity 5/9 Risk: low Services US · CN · EU verified 2026-08-10 · 4 Sources (0 independent)

1 · What it gives

HTA dossier preparation assembles the health-economic evidence package a biopharma manufacturer must submit to a national health technology assessment body — NICE in the UK, G-BA in Germany, CADTH in Canada — to win a pricing and reimbursement decision after a drug or device already has regulatory marketing authorization. A NICE Single Technology Appraisal gives manufacturers a hard 56-calendar-day deadline to submit a full evidence dossier once scoping is complete, and Germany’s AMNOG dossier for the G-BA carries similarly compressed timelines. One specialty consultancy has prepared over 370 HTA submission dossiers, more than 135 to NICE alone; another has built an in-house AI tool that compressed a full German AMNOG dossier’s production time to three months. This is a distinct advisory service from the CMC regulatory filing and market-access manufacturing services already covered on this site — HTA dossier work happens after regulatory approval, building the separate economic case a payer needs to agree to reimburse the product, not the safety/efficacy case a regulator needs to approve it.

Key directions of HTA dossier preparation:

  1. Systematic evidence review (Systematic Evidence Review): structured literature reviews and network meta-analyses building the clinical comparator evidence base an HTA submission requires.
  2. Cost-effectiveness and budget-impact modeling (Cost-Effectiveness Modeling): health-economic models calculating a therapy’s cost-per-outcome and budget impact against national HTA methodology standards.
  3. AI-assisted dossier generation (AI-Assisted Dossier Generation): AI tools that convert structured clinical trial data into the narrative sections an HTA dossier requires, compressing production timelines.
  4. Payer and HTA stakeholder engagement (Stakeholder Engagement): structured advisory support for the negotiation and scientific-advice stages of an HTA submission process.

Sectoral value chain#

[regulatory marketing authorization] ──> [evidence synthesis] ──> [economic modeling] ──> [dossier assembly]
                                                                          │
                                                              (HTA body statutory deadline)
                                                                          │
                                                                          ▼
[pricing/reimbursement decision] <─── [HTA body submission] <──┘

Value chain levels#

LevelDescriptionKey inputs/outputs
Scopingdefining the HTA submission’s comparator and population scopeIn: regulatory approval, target HTA body requirements. Out: submission scope document.
Evidence synthesissystematic review and network meta-analysis of clinical dataIn: clinical trial data, published literature. Out: synthesized evidence base.
Economic modelingcost-effectiveness and budget-impact model constructionIn: evidence base, cost data. Out: health-economic model outputs.
Dossier assemblycompiling the full submission document per HTA body formatIn: evidence, model outputs. Out: complete HTA dossier.
Submission & reviewformal submission and response to HTA body evidence requestsIn: complete dossier. Out: HTA body evaluation, clarification responses.
Decision & negotiationpricing/reimbursement decision and any negotiated agreementIn: HTA evaluation. Out: reimbursement decision, price agreement.

Cross-cutting technologies:

  • AI-assisted dossier generation (AI-Assisted Dossier Generation): software converting structured clinical data into HTA-required narrative documentation.
  • Cost-effectiveness modeling (Health-Economic Modeling): statistical and economic models calculating cost-per-outcome against HTA methodology standards.
  • AMNOG/NICE submission workflow (Statutory-Deadline Submission Workflow): structured project-management processes built around each HTA body’s specific statutory submission deadlines.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 6 steps

  1. 1
    Scoping
    The consultancy and manufacturer agree the submission’s target population, comparator therapies and outcome measures based on the HTA body’s published scoping document.
  2. 2
    Evidence synthesisSynthesis & conversion
    A systematic literature review and network meta-analysis assembles the clinical evidence base, including indirect comparisons where no direct head-to-head trial against every relevant comparator exists.
    Who can do this step matched automatically
    163,050 tonnes
    “Uniquely equipped with the credentials for the R&D, design, and production of both high-efficiency dust filtration materials and SCR denitration catalysts, as well as for the …”
    ✓ ISO 9001 30,000 tons per industrial scale
    “Enzymes for Protein Hydrolysis”
    “2026-06-28 [BIOCATALYST LEADERSHIP: How Enzymes are Propelling India's Pharma Bio Spectrum - business - Read this story on Magzter.com — A brief mention of Aum Enzymes or Infinita …”
  3. 3
    Economic modeling
    A cost-effectiveness and budget-impact model is built to the specific methodology the target HTA body requires, calculating cost-per-outcome and national budget impact.
  4. 4
    Dossier assemblyRegulatory & certification
    Evidence synthesis and modeling outputs are compiled into the complete dossier document, in the exact format and section structure the HTA body mandates — increasingly assisted by AI tools that draft narrative sections from structured data.
    Registration in Russia / EAEU: Regulation
  5. 5
    Submission
    The complete dossier is formally submitted within the HTA body’s statutory deadline — 56 calendar days for a NICE STA following scoping — and the consultancy manages responses to any evidence clarification requests.
  6. 6
    Decision and negotiation
    The HTA body issues its pricing/reimbursement evaluation, with the consultancy supporting the manufacturer through any negotiation or appeal stage before a final reimbursement decision and price agreement.

4 · Who delivers

Matched suppliers (matched automatically)

Biological PreparationsUnited KingdomProduceractive
AGRIBIO+CameroonProduceractive
FreseniusGermanyProduceractive
National Animal Genetic Resources Centre & Data Bank (NAGRC&DB)UgandaResearch / RTOactive

In the services and supply catalogue 2 · paid service

Consulting & market access · Regulatory & certification

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Costello Medical🇬🇧 UKFull HTA evidence packages (strategy through dossier writing)370+ HTA dossiers delivered, 135+ to NICE; B Corp certified; King’s Award for Enterprise 2025Commercial
Kintiga🇬🇧 UKEPRI AI-assisted AMNOG/NICE/JCA dossier toolAI-compressed AMNOG dossier production to 3 months; ~90 employees, 2 continentsCommercial
Lumanity🇺🇸 USAHEOR and market-access advisoryFormed 2020 via Cello Health/BresMed/Guidemark Health merger; 1,200+ employeesCommercial
VantEdge Access🇺🇸 USAAI-enabled HTA intelligence platformUS/Canada/EU-5 coverage; combines AI tooling with senior HEOR consultingCommercial

5 · Rules & route to market

United States

The US HTA landscape is shaped by a non-mandated but increasingly influential nonprofit assessor, with specialty consultancies built specifically around navigating its evidence expectations alongside private payer requirements.

ICER’s non-mandatory but influential role, AI-native and established consultancy models, private-payer evidence requirements#

  • Lumanity (Bethesda, founded 2020): formed through the merger of several established health-economics and market-access firms including Cello Health and BresMed, with 1,200+ employees across the US, UK, Europe and India providing health-economics-and-outcomes-research services.
  • VantEdge Access (Illinois, hubs in Chicago/Oak Brook and Paris): combines AI-enabled HTA intelligence with consulting expertise across the US, Canada and EU-5 markets, supporting biopharma teams through development, launch and lifecycle market-access strategy.
  • ICER’s non-mandatory influence: unlike NICE or other statutory HTA bodies, ICER’s cost-effectiveness assessments are not mandated in the US, but its value-based price estimates increasingly shape payer negotiations and coverage decisions.

European Union

Europe hosts the field’s most established specialty consultancies, built around the UK’s NICE and Germany’s AMNOG processes, both running on strict statutory deadlines.

NICE 56-day statutory deadline, AMNOG AI-compressed dossier production, B Corp-certified global consultancy model#

  • Costello Medical (Cambridge, UK): a B Corp-certified consultancy with offices spanning Europe, Asia-Pacific and North America, having developed over 370 HTA submission dossiers with 135+ submitted to NICE alone, and winner of the King’s Award for Enterprise in International Trade (2025).
  • Kintiga (UK, ~90 employees): a pan-European market-access consultancy whose in-house AI tool (EPRI) compressed a full German AMNOG HTA dossier’s production to three months, alongside direct AMNOG negotiation support.
  • NICE’s 56-day statutory deadline: manufacturers face a hard 56-calendar-day deadline to submit a full evidence dossier for a NICE Single Technology Appraisal once scoping concludes, the timeline pressure driving demand for specialty dossier-preparation services.

China

No confirmed China-domiciled HTA-specialist consultancy was found operating independently; international consultancies with China offices serve manufacturers navigating the National Reimbursement Drug List process instead.

NRDL as the reimbursement gateway, international-firm China offices, no confirmed domestic specialist#

  • NRDL as the reimbursement gateway: inclusion on China’s National Reimbursement Drug List, administered by the National Healthcare Security Administration, determines whether a product is reimbursed nationally and is often the only path to prescription within public hospitals.
  • NHDRC evaluation role: China’s National Health Development Research Center provides technical HTA consultancy to health policy-makers, with a panel of health-economic experts scoring each eligible drug — a government research-institution role rather than a private-vendor service.
  • International firms’ China presence: established international HTA consultancies maintain Shanghai offices to serve manufacturers navigating NRDL submissions, but no independently confirmed China-domiciled specialist firm was found — left qualitative pending a real candidate.

6 · Money: tenders & grants

GrantAdditional activities for the European Partnership of Agriculture of Data
European Commission · EU
Nov 26, 2026
3 days
GrantBoosting Innovative GEOINT - Science & Technology Broad Agency Announcement (BIG-ST BAA)
National Geospatial-Intelligence Agency · United States
Dec 14, 2026
21 days
GrantNSF Scholarships in Science, Technology, Engineering, and Mathematics Program
U.S. National Science Foundation · United States
Mar 2, 2027
99 days
GrantOpen topic: Using the Circular Cities and Regions Initiative to strengthen urban manufacturing in support of …
European Commission · EU
Apr 8, 2027
136 days
GrantPowering Affordable Reliable Technology (PART) Energy Program
Rural Utilities Service · United States
rolling

7 · Tech stack & innovations

The category’s technical work spans health-economic methodology and, increasingly, AI tooling that compresses the traditionally document-heavy dossier-writing process.

  1. Cost-effectiveness modeling infrastructure (Health-Economic Model Construction):
    • Modelers build cost-effectiveness and budget-impact models specific to each HTA body’s required methodology — NICE’s reference-case requirements differ from G-BA’s AMNOG framework, requiring jurisdiction-specific model construction rather than a single reusable template.
    • Network meta-analysis techniques let a dossier compare a therapy against multiple relevant comparators even when no direct head-to-head trial exists.
  2. AI-assisted dossier drafting (Structured-to-Narrative AI Conversion):
    • AI tools convert structured clinical trial data directly into the narrative sections an HTA dossier’s required format demands, compressing a process that traditionally took many months of manual medical writing.
    • This is a live technical differentiator: one firm’s AI-assisted workflow completed a full AMNOG dossier in three months, a significantly compressed timeline versus traditional manual preparation.
  3. Statutory-deadline project management (Multi-Jurisdiction Submission Workflow):
    • Firms operating across multiple HTA bodies manage genuinely different statutory deadlines and evidence-format requirements in parallel — a NICE STA’s 56-day window differs from AMNOG’s own compressed timeline — requiring dedicated project infrastructure rather than a single generic consulting workflow.

Sources 4 · 0 independent · 4 producer sites

Producers' own sites 4

  1. Costello medical producer checked 2026-08-10 · link not kept
  2. Kintiga producer checked 2026-08-10 · link not kept
  3. Lumanity producer checked 2026-08-10 · link not kept
  4. Vantedge access producer checked 2026-08-10 · link not kept